

The Function of Vitamin D Receptor in Vitamin D Action

Shigeaki Kato

Institute of Molecular and Cellular Biosciences, The University of Tokyo, Yayoi-cho, Bunkyo-ku, Tokyo, 113-0032; and CREST, Japan Science and Technology Corporation, 4-1-8 Honcho, Kawaguchi, Saitama 332

Received January 21, 2000, accepted January 28, 2000

Vitamin D has roles in a variety of biological actions such as calcium homeostasis, cell proliferation and cell differentiation to many target tissues. Most of these biological actions of vitamin D are now considered to be exerted through the nuclear vitamin D receptor (VDR)-mediated control of target genes. VDR belongs to the nuclear hormone receptor superfamily and acts as a ligand-inducible transcription factor. For the ligand-induced transactivation of VDR, coactivator complexes have recently been shown to be essential. The function of VDR as a ligand-induced transcription factor is overviewed, and the phenotype of VDR gene knock-out mice and the VDR-mediated transcriptional and negative regulation of the key enzyme in vitamin D biosynthesis are also described, based mainly on our recent findings, to gain a better understanding of the function of VDR in the transcriptional control of vitamin D target genes.

Key words: nuclear receptor, VDR KO mice, vitamin D, vitamin D 1α -hydroxylase, transcription factor.

1. Introduction

Vitamin D has roles in a variety of biological actions such as calcium homeostasis, cell proliferation, and cell differentiation to many target tissues. Especially, in calcium homeostasis and bone metabolism, vitamin D has long been believed to be a prime regulatory factor (1, 2), since it is well known that vitamin D deficiency causes rickets with growth retardation, impaired bone formation, and hypocalcemia. Rickets is caused by a dietary vitamin D deficiency, and is also a hereditary disease. Up until now, hereditary rickets has been classified into three types. The genes responsible for vitamin D-dependent rickets type II and X-linked hypophosphatemic vitamin D-resistant rickets (HYD) have been identified as the VDR gene (3) and the PEX gene (4), respectively. Recently, we found that the third kind of hereditary rickets, the vitamin D-dependent rickets type I, is caused by genetic mutations in the gene for 25-hydroxyvitamin D₃ 1α -hydroxylase [1α (OH)ase] (5, 6), as described below (Fig. 1).

Most of the biological actions of vitamin D are now thought to be exerted through the nuclear vitamin D receptor (VDR)-mediated control of target genes. VDR belongs to the nuclear hormone receptor superfamily and acts as a ligand-inducible transcription factor (7). This superfamily comprises more than 60 nuclear receptors for lipophilic ligands such as steroid/thyroid hormones, vitamin A and vitamin D. In this review, the function of VDR is described based mainly on our findings and those of others concerning transcriptional control.

2. Biosynthesis of vitamin D

The precursor of vitamin D, 7-dehydrocholesterol, is biosynthesized from cholesterol, then converted to vitamin D₃ by UV light on the skin. Vitamin D is also ingested in the diet as Vitamin D₂ (ergocalciferol), mainly from plants, and vitamin D₃ (cholecalciferol) from animals (8, 9). A hormonal form of vitamin D, $1\alpha,25(\text{OH})_2\text{D}_3$, is metabolically formed through two hydroxylation steps at the final stage (Fig. 1) (see references in Refs. 5 and 6). First, vitamin D is hydroxylated in the liver to 25-dihydroxyvitamin D₃ [$25(\text{OH})\text{D}_3$], which is subsequently hydroxylated in the kidney to $1\alpha,25(\text{OH})_2\text{D}_3$. For the metabolic inactivation of $25(\text{OH})\text{D}_3$ or $1\alpha,25(\text{OH})_2\text{D}_3$, the 24-hydroxylation to form $24,25(\text{OH})_2\text{D}_3$, or $1\alpha,24,25(\text{OH})_3\text{D}_3$ is the first step in the degradation of vitamin D. The serum level of $1\alpha,25(\text{OH})_2\text{D}_3$ is held constant in the normal state, and is strictly regulated in response to factors controlling calcium homeostasis. The regulation of $1\alpha,25(\text{OH})_2\text{D}_3$ and $24,25(\text{OH})_2\text{D}_3$ production by these factors is conducted by altering the activities of the enzymes that hydroxylate vitamin D derivatives. Vitamin D₃-25-hydroxylase (CYP27) catalyzes hepatic 25-hydroxylation, and renal 1α -hydroxylation is catalyzed by 25-hydroxyvitamin D₃ 1α -hydroxylase [$1\alpha(\text{OH})\text{ase}$]. The first step in the metabolic inactivation of vitamin D metabolites by 24-hydroxylation is catalyzed by $25(\text{OH})\text{D}_3$ -24-hydroxylase (CYP24) (6).

3. Molecular mechanism of transcriptional control by the vitamin D receptor

The hormonal form of vitamin D, $1\alpha,25$ -dihydroxyvitamin D₃ [$1\alpha,25(\text{OH})_2\text{D}_3$], acts as a ligand for the vitamin D receptor (VDR), and the liganded VDR activates target gene expression at the transcriptional level (Fig. 2) (10, 11). VDR forms homodimers or heterodimers with one of three retinoid X receptors (RXR α , RXR β , RXR γ). The VDR homodimer or VDR-RXR heterodimer binds to specific enhancer elements, referred to as vitamin D response elements

Correspondence should be addressed to. Shigeaki Kato, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032. Tel: +81-3-5841-8478, Fax +81-3-5841-8477, E-mail uskato@mail.ecc.u-tokyo.ac.jp

Rickets related to vitamin D




Fig. 1 Vitamin D-related rickets. The biosynthetic pathway of $1,25(\text{OH})_2\text{D}_3$ and the mode of $1,25(\text{OH})_2\text{D}_3$ action are illustrated. Defects in these processes cause rickets. Nutritional vitamin D deficiency and the defect in renal $1\alpha(\text{OH})\text{ase}$ activity by genetic mutations (VDDR I patients) result in a short supply of vitamin D. The mutated VDR in VDDR II patients is unable to respond to $1,25(\text{OH})_2\text{D}_3$, resulting in rickets. The precursor of vitamin D, 7-dehydrocholesterol, is biosynthesized from cholesterol, then converted into vitamin D_3 by UV light on the skin. Vitamin D is also ingested from the diet as Vitamin D_2 (ergocalciferol), mainly from plants and vitamin D_3 (cholecalciferol) from animals. A hormonal form of vitamin D that acts as a ligand specific for VDR, $1,25(\text{OH})_2\text{D}_3$, is formed metabolically through two hydroxylation steps at the final stage. First, vitamin D is hydroxylated in the liver to 25-dihydroxyvitamin D_3 [$25(\text{OH})\text{D}_3$] by the vitamin D_3 -25-hydroxylase (CYP27). Subsequently, 25-hydroxyvitamin D_3 1 α -hydroxylase [$1\alpha(\text{OH})\text{ase}$] in the kidney undergoes conversion into $1,25(\text{OH})_2\text{D}_3$.

(VDREs), for $1,25(\text{OH})_2\text{D}_3$ -induced transactivation (12). For ligand-induced transactivation by VDR, coactivators that interact with VDR in a ligand-dependent way have recently been shown to be essential for the formation of the initial transcription complex with RNA polymerase II (Figs. 2 and 3) (13). They include the SRC-1/TIF2 160 kDa protein family, CBP/p300 protein family, SRA (a RNA coactivator), and others (see references in Refs. 13–16). Most interestingly, these coactivators themselves are histone acetylases (HATs) that modulate chromatin structure to activate gene expression (17, 18). These coactivators are speculated to form a complex. More recently, another coactivator complex has been identified as the DRIP/TRAP complex, which has no HAT activity (13, 19, 20). In contrast to coactivators, corepressors, SMRT and NCoR have been found to associate with ligand-unbound thyroid receptor (TR) and the all-trans retinoic acid receptor (RAR) to repress their ligand-induced transactivation functions (21, 22) (Fig. 3). However, these corepressors appear not to interact with ligand-unbound VDR (10).

4. Physiological function of VDR in intact animals—Lessons from Vitamin D receptor knock-out mice

Although the function of VDR has been studied intensively in cell culture systems (10, 11), it was unclear whether such findings reflect the function of VDR in intact animals. Especially, the actions of $1,25(\text{OH})_2\text{D}_3$ in bone formation and metabolism have been well described in adult animals; however, the physiological role of VDR in target tissues during development and in intact animals had not yet been established. Moreover, an animal model of vitamin D-dependent rickets type II patients was absent (23).

We, therefore, generated mice deficient in VDR by gene targeting in order to investigate the function of VDR *in vivo* (24). Like vitamin D, vitamin A has been shown to play a critical role in growth and development, especially in skeletal formation during embryogenesis (25). In fact, the inactivation of one (RAR γ) of six vitamin A nuclear receptors results in tracheal cartilage malformation and homeotic transformations along the rostral axial skeleton during embryogenesis. However, no bone malformations or overt phenotypic abnormalities were seen in the VDR $^{-/-}$ fetuses (data not shown). Unexpectedly, VDR null mutant mice do not differ from their heterozygous or wild-type littermates in growth rate or behavior, and seem functionally normal after birth until weaning. However, after weaning (about 3 weeks), the VDR null mutant mice display typical features of rickets such as growth retardation and impaired bone formation, and most of them die by 15 weeks due to unknown reasons. However, no overt abnormalities are found in the heterozygotes even at 6 months, in good agreement with type II rickets as a recessive trait in humans (23). By 7 weeks, all of the VDR null mutant mice develop alopecia and poor whiskers as typical features of rickets, and most of them display a flat face with a shorter nose. For null mutant mice between 7 and 13 weeks of age, no apparent abnormalities are found by histological analysis in VDR-expressing tissues other than bone and skin, including intestine, kidney, brain, and spleen, although these tissues are considered to be direct target tissues for the actions of vitamin D (1, 2).

Observations in VDR null mutant mice by us (24) and other (26) are similar to those of a human hereditary, recessive disease, vitamin D dependency type II, in which mutations in the VDR gene have been identified in several families (3), although, unlike in VDR KO mice, this disease is not lethal. As these patients exhibit rickets with hypocalcemia, hypophosphatemia, and elevated serum levels of alkaline phosphatase (ALP), four week-old VDR-KO mice show reduced serum levels of calcium and phosphorus with a markedly elevated serum ALP activity. Radiographic analysis of the skeletal tissues of VDR null mutant mice reveal a loss of bone density. Typical features of advanced rickets are observed in gross appearance and on X-ray analysis of tibia and fibula, including widening of epiphyseal growth plates, thinning of the cortex, and fraying, cupping and widening of the metaphysis. In addition, orderly columns of hypertrophic chondrocytes are lost and the cartilage layers are widened with inadequate mineralization. In cancellous bone adjacent to the growth plates, marked increases in the extent and width of the osteoid seams are noted, and the bone surfaces are surrounded by numerous osteoblastic cells. Most strikingly, the numbers of




Fig 2. Schema of the molecular mechanism of vitamin D action through VDR-mediated gene expression.




Fig 3. Ligand-bound VDR forms a transcription initiation complex to activate gene expression. For ligand-induced transactivation, VDR forms a complex with the basic transcriptional machinery and a coactivator complex in the promoter of the target gene for vitamin D. Two coactivator complexes, with and without HAT activity, have been identified to date.

osteoclasts do not appear to be affected by VDR inactivation, although it has been well established in *in vitro* cell culture systems that vitamin D is a most potent inducer of osteoclast differentiation from precursor cells in the spleen (27, 28). Moreover, when the VDR KO mice were fed a high calcium and phosphate diet to rescue the lowered levels of serum minerals, the impaired mineralization was recovered except in the affected cartilage (Yagishita *et al.*, unpublished results). These findings in the bones of VDR KO mice reveal that the direct target of vitamin D action in bone is the chondrocyte, and that the mineralization to form bone is an indirect effect of vitamin D mediated through serum minerals (Fig. 4)

Together, these findings in VDR KO mice establish that most vitamin D actions known to date are mediated through VDR, and that the vitamin D-VDR system is essential only after weaning.

5. 25-Hydroxyvitamin D₃ 1 α -hydroxylase [1 α (OH)ase] as a key enzyme in vitamin D synthesis

The serum level of 1 α ,25(OH)₂D₃ is strictly regulated in

response to calcium requirement in the body. Several enzymes regulated by several factors including 1 α ,25(OH)₂D₃ are involved in the synthesis and metabolism of 1 α ,25(OH)₂D₃. The activities of 25(OH)D 1 α -hydroxylase and 24-hydroxylase are regulated negatively and positively by 1 α ,25(OH)₂D₃ (6). In VDR null mutant mice, a marked increase in serum 1 α ,25(OH)₂D and a clear reduction in serum 24,25(OH)₂D are seen, suggesting an increased activity of 1 α (OH)ase and reduced activity of 24-hydroxylase (24). Thus, it is clear that the expression of these enzymes is under the negative control of 1 α ,25(OH)₂D-bound VDR. Indeed, based on experiments using VDR KO mice, we provided the first report of the cloning of the cDNA encoding mouse 25(OH)D 1 α -hydroxylase by a newly developed expression cloning method (29). This method is based on the principle that only 1 α ,25(OH)₂D₃, not any precursors or metabolites, can activate the transactivation function of VDR by direct binding. Therefore, when 25(OH)D₃ is added to the medium, VDR is activated only in cells expressing 1 α (OH)ase. At the same time as our mouse cDNA cloning in 1997, several groups using RT-PCR methods reported

the cloning of cDNAs encoding rat and human $1\alpha(\text{OH})\text{ase}$, confirming the previously described biochemical characterization of $1\alpha(\text{OH})\text{ase}$ as a cytochrome p450 (30, 31). The predicted amino acid sequences revealed that $1\alpha(\text{OH})\text{ase}$ proteins harbor a mitochondrial target signal and two conserved regions (the sterol-binding domain and the heme-binding domain), and show significant homology throughout the entire amino acid sequence with the p450 enzymes. Mouse $1\alpha(\text{OH})\text{ase}$ exhibits the greatest homologies to the vitamin D hydroxylases: 41.7% homology to rat vitamin D_3 -25-hydroxylase (CYP27), and 31.6% homology to the mouse $25(\text{OH})\text{D}_3$ -24-hydroxylase (CYP24). The organization of the human $1\alpha(\text{OH})\text{ase}$ gene comprises nine exons extending over 5 kbp (5), and resembles other p450 enzymes that hydroxylate steroids.

From clinical studies, genetic defects in the enzymes responsible for the biosynthesis of $1\alpha,25(\text{OH})_2\text{D}_3$ are considered to evoke vitamin D deficiency. A group of hereditary rickets patients exhibits low serum levels of $1\alpha,25(\text{OH})_2\text{D}_3$, while $25(\text{OH})\text{D}_3$ levels are normal or high, and these pati-

ents recover with only supplementation of physiological doses of $1\alpha,25(\text{OH})_2\text{D}_3$ or $1\alpha(\text{OH})\text{D}_3$. This autosomal recessive disease is referred to as pseudovitamin D-deficient rickets (PDDR), also known as vitamin D-dependency type I (VDDR1) (32). As mutations in the $1\alpha(\text{OH})\text{ase}$ gene resulting in the loss of its enzymatic activity were thought to be a cause of hereditary rickets, we tested this idea using cloned human $1\alpha(\text{OH})\text{ase}$ cDNA. FISH analysis showed that this gene lies on chromosome 12q13.3. Interestingly, this locus closely matches the chromosomal localization of a putative gene that had been mapped as responsible for type I rickets by linkage analysis of a group of Canadian patients (33). Furthermore, we found that distinct homozygous missense mutations in the human $1\alpha(\text{OH})\text{ase}$ gene that abolish $1\alpha(\text{OH})\text{ase}$ activity are present in four different Japanese type I rickets patients (5), and, more recently, we further identified hetero-compound type mutations in other patients (34). Interestingly, mutation sites that cause a complete loss of enzymatic activity were found widely over the entire region of the $1\alpha(\text{OH})\text{ase}$ protein (5, 30, 34, 35), although the regions essential for the enzymatic activity have been identified by a biochemical approach (36, 37). Thus, these observations establish that an inactive genetic mutation of human $1\alpha(\text{OH})\text{ase}$ causes type I hereditary rickets, and clearly indicate that $1\alpha(\text{OH})\text{ase}$ is a critical enzyme in vitamin D biosynthesis.

6. Negative regulation of $1\alpha(\text{OH})\text{ase}$ gene expression by VDR

The activity of $1\alpha(\text{OH})\text{ase}$ was first identified in kidney homogenates, and kidney was thought to be the sole tissue expressing $1\alpha(\text{OH})\text{ase}$, and the proximal convoluted tubule cells were identified as its location in kidney (38). Northern blot analysis using the cloned cDNA demonstrated that this gene is expressed abundantly in kidney, while expression was almost undetectable in extra-renal tissues of mice and humans. Quantitative RT-PCR analysis suggests that the $1\alpha(\text{OH})\text{ase}$ gene is expressed in many extrarenal tissues at very low levels (39). As $1\alpha,25(\text{OH})_2\text{D}_3$ plays a primary role in calcium homeostasis, the renal activity of $1\alpha(\text{OH})\text{ase}$ is positively regulated by calcitropic hormones, responding to serum calcium levels (40). $1,25(\text{OH})_2\text{D}_3$ has




Fig. 4 Direct and indirect actions of vitamin D in target tissues. Our findings in VDR KO mice suggest direct and indirect actions of vitamin D in animals. Most of the actions of vitamin D in bone formation appear to be mediated indirectly through the elevated serum calcium levels induced by vitamin D, however, cartilage development depends on a VDR function independent of serum calcium status.




Fig. 5 A proposed molecular mechanism for the regulation of $1\alpha,25(\text{OH})_2\text{D}_3$ biosynthesis by 25-hydroxyvitamin D_3 , 1α -hydroxylase and $25(\text{OH})\text{D}_3$ -24-hydroxylase. Negative regulation of $1\alpha(\text{OH})\text{ase}$ gene expression by $1\alpha,25(\text{OH})_2\text{D}_3$ does not occur in mice lacking VDR (VDR knock-out mice), suggesting the possibility that a negative VDRE is present in the promoter of the $1\alpha(\text{OH})\text{ase}$ gene. The positive VDRE has been identified in the promoter of the $25(\text{OH})\text{D}_3$ -24-hydroxylase gene. The levels of serum $1\alpha,25(\text{OH})_2\text{D}_3$ are positively and negatively regulated through these VDREs binding ligated VDR.

TABLE I. DNA sequences of negative vitamin D response elements (nVDREs). The previously reported nVDREs are shown except $1\alpha(\text{OH})\text{ase}$ nVDRE, which has not yet been delineated to a core nVDRE motif.

gene	nVDRE		
	response element		
Avian PTH	GGGTCA	GGA	GGGTGT
Human PTH	GGTTCA	AAG	CAGACA
Mouse osteocalcin	GGGCAA	ATG	AGGACA
Rat bone sialoprotein	AGGGTT	TAT	AGGTCA
PKA inhibitor	ATGTTG	CTG	AGGTCA
Rat PTHrP-proximal	AGGTTA	CTC	AGTGAA
Rat PTHrP-distal	GGGTGG	AGA	GGGGTG
human vitamin D 1α -hydroxylase	CCCATTAACCCACCTGCCATCTG		

been well characterized as a negative regulator of the renal activity of $1\alpha(\text{OH})\text{ase}$ (41). Our study using VDR knock-out mice showed that $1\alpha,25(\text{OH})_2\text{D}_3$ acts at the transcriptional level, and this negative regulation requires the liganded-VDR, since the gene expression of mouse $1\alpha(\text{OH})\text{ase}$ is remarkably up-regulated in VDR KO mice (29, 39) (Fig. 5). In contrast, calcitropic hormones such as calcitonin and PTH are known to induce the activity of $1\alpha(\text{OH})\text{ase}$, and cAMP has been demonstrated to be involved in this positive regulation by PTH, suggesting the possible involvement of the protein kinase A signaling pathway in the positive regulation (40). These findings are further supported by the recent observations that the proximal promoters of the human and mouse $1\alpha(\text{OH})\text{ase}$ genes confer positive responses to PTH and calcitonin (42, 43). Moreover, in the human promoter we identified a kidney cell-specific negative regulatory element to $1\alpha,25(\text{OH})_2\text{D}_3$ (Murayama *et al.*, unpublished results), although there are neither consensus negative VDREs nor significantly related sequences (see Table I) (44, 45). The overexpression of VDR along with RXR potentiates this negative regulation by $1\alpha,25(\text{OH})_2\text{D}_3$. Together with the findings of the negative regulation in VDR KO mice, these observations clearly indicate that VDR is essential for the negative regulation of the $1\alpha(\text{OH})\text{ase}$ gene by $1\alpha,25(\text{OH})_2\text{D}_3$. However, gel-shift analysis with nuclear extracts and recombinant receptor proteins showed that this negative VDRE does not bind VDR or the VDR-RXR heterodimer directly, but binds an unknown nuclear factor(s) that is expressed in a tissue-specific manner (Murayama *et al.*, unpublished results). Taken together, these observations suggest that the transactivation function of DNA binding regulatory factor(s) bound to this negative VDRE is indirectly suppressed by ligand-bound VDR, probably through coactivators and/or repressors as discussed above. Currently, this hypothesis is under investigation to identify the factor bound to the negative VDRE in the human $1\alpha(\text{OH})\text{ase}$ gene promoter.

I would like to thank Drs. T. Yoshizawa and K. Sekine for the

VDR KO mouse study, and Drs. K. Takeyama, S. Kitanaka, and A. Murayama for the $1\alpha(\text{OH})\text{ase}$ gene project, and express sincere gratitude to all the members in my laboratory and my colleagues worldwide for collaborating in these projects.

REFERENCES

1. Bouillon, R., Okamura, W.H., and Norman, A.W. (1995) Structure-function relationships in the vitamin D endocrine system. *Endocr Rev* 16, 200–257
2. Walters, M.R. (1992) Newly identified actions of the vitamin D endocrine system. *Endocr. Rev.* 13, 719–764
3. Hughes, M.R., Malloy, P.J., Kieback, D.G., Kesterson, R.A., Pike, J.W., Feldman, D., and O'Malley, B.W. (1988) Point mutations in the human vitamin D receptor associated with hypocalcemic rickets. *Science* 242, 1702–1705
4. The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypocalcemic rickets. *Nat. Genet.* 11, 130–136
5. Kitanaka, S., Takeyama, K., Murayama, A., Sato, T., Okumura, K., Nogami, M., Hasegawa, Y., Niimi, H., Yanagisawa, J., Tanaka, T., and Kato, S. (1998) Inactivating mutations in the human 25-hydroxyvitamin D3 1 α -hydroxylase gene in patients with pseudovitamin D-deficient rickets. *N. Engl. J. Med.* 338, 653–661
6. Kato, S., Yanagisawa, J., Murayama, A., Kitanaka, S., and Takeyama, K. (1998) The importance of 25-hydroxyvitamin D3 1 α -hydroxylase gene in vitamin D-dependent rickets. *Curr. Opin. Nephrol. Hypertension* 7, 377–383
7. Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. *et al.* (1995) The nuclear receptor superfamily: the second decade. *Cell* 83, 835–839
8. Norman, A.W., Roth, J., and Orchi, L. (1982) The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins). *Endocr Rev* 3, 331–366
9. DeLuca, H.F. (1986) The metabolism and functions of vitamin D. *Adv. Exp. Med. Biol.* 196, 361–375
10. Haussler, M.R., Whitfield, G.K., Haussler, C.A., Hsieh, J.C., Thompson, P.D., Selznick, S.H., Dominguez, C.E., and Jurutka, P.W. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *J. Bone Miner. Res.* 13, 325–349
11. Darwish, H. and DeLuca, H.F. (1993) Vitamin D-regulated gene expression. *Crit. Rev. Eukaryotic Gene Express.* 3, 89–116
12. Ebihara, K., Masuhiro, Y., Kitamoto, T., Suzawa, M., Uematsu, Y., Yoshizawa, T., Ono, T., Harada, H., Matsuda, K., Hasegawa, T., Masushige, S., and Kato, S. (1996) Intron retention generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway. *Mol. Cell. Biol.* 16, 3393–3400
13. Freedman, L.P. (1999) Increasing the complexity of coactivation in nuclear receptor signaling. *Cell* 97, 5–8
14. Rachez, C. *et al.* (1999) Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. *Nature* 398, 824–828
15. Yanagisawa, J., Yanagi, Y., Masuhiro, Y., Suzawa, M., Toriyabe, T., Kashiwagi, K., Watanabe, M., Kawabata, M., Miyazono, K., and Kato, S. (1999) Convergence of TGF β and vitamin D signaling pathways on SMAD proteins acting as common transcriptional co-activators. *Science* 283, 1317–1321
16. Takeyama, K., Masuhiro, Y., Fuse, H., Endoh, H., Murayama, A., Kitanaka, S., Suzawa, M., Yanagisawa, J., and Kato, S. (1999) Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. *Mol. Cell. Biol.* 19, 1049–1055
17. Chen, H., Lin, R.J., Schiltz, R.L. *et al.* (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* 90, 569–580
18. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Glass,

- B., Lin, C., Heyman, A., Rose, W., Glass, K., and Rosenfeld, G. (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* **85**, 403–414
19. Rachez, C., Lemon, D., Suldan, Z., Bromleigh, V., Gamble, M., Naar, M., Erdjument, H., Tempst, P., and Freedman, P. (1999) Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. *Nature* **398**, 824–828
 20. Yuan, C.X., Ito, M., Fondell, J.D., Fu, Z., and Roeder, R.G. (1998) TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptor in a ligand-dependent fashion. *Proc. Natl. Acad. Sci. USA* **95**, 7939–7944
 21. Horlein, A.J. *et al.* (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor corepressor. *Nature* **377**, 397–404
 22. Nagy, L., Kao, H.Y., Chakravarti, D., Lin, R.J., Hassig, C.A., Ayer, D.E., Schreiber, S.L., and Evans, R.M. (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. *Cell* **89**, 373–380
 23. Malloy, P.J., Hochberg, Z., Tiosano, D., Pike, J.W., Hughes, M.R., and Feldman, D. (1990) The molecular basis of hereditary 1,25-dihydroxyvitamin D₃ resistant rickets in seven related families. *J. Clin. Invest.* **86**, 2071–2079
 24. Yoshizawa, T., Handa, Y., Uemasu, Y., Takeda, S., Sekine, K., Yoshihara, Y., Kawakami, T., Arioka, K., Sato, H., Uchiyama, Y., Masushige, S., Fukamizu, A., Matsumoto, T., and Kato, A. (1997) Impaired bone formation and uterine hypoplasia with growth retardation after weaning in mice lacking the vitamin D receptor. *Nat. Genet.* **16**, 391–396
 25. Kastner, P., Mark, M., and Chambon, P. (1995) Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? *Cell* **83**, 859–869
 26. Li, Y.C., Pirro, A.E., Amling, M., Dellling, G., Baron, R., Bronson, R., and Demay M.B. (1997) Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proc. Natl. Acad. Sci. USA* **94**, 9831–9835
 27. Suda, T. and Takahashi, N. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocr. Rev.* **20**, 345–357
 28. Takahashi, N., Udagawa, N., Akatsu, T. *et al.* (1991) Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. *Endocrinology* **128**, 1792–1796
 29. Takeyama, K., Kitanaka, S., Sato, T., Kobori, M., Yanagisawa, J., and Kato, S. (1997) 25-Hydroxyvitamin D₃ 1 α -hydroxylase and vitamin D synthesis. *Science* **277**, 1827–1830
 30. Fu, G.K., Lin, D., Zhang, M.Y.H., Bikle, D.D., Shackleton, C.H.L., Miller, W.L., Portale, A.A. (1997) Cloning of human 25-hydroxyvitamin D-1 α -hydroxylase: a mutations causing vitamin D-dependent rickets type 1. *Mol. Endocrinol.* **11**, 1961–1970
 31. Monkawa, T., Yoshida, T., Wakino, S., Shinki, T., Anazawa, H., DeLuca, F.F., Suda, T., Hayashi, M., and Saruta, T. (1997) Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D₃ 1 α -hydroxylase. *Biochem. Biophys. Res. Commun.* **239**, 527–533
 32. Scriver, C.R., Reade, T.M., DeLuca, H.F., and Hamstra, A.J. (1978) Serum 1,25-dihydroxyvitamin D levels in normal subjects and patients with hereditary rickets or bone disease. *N. Engl. J. Med.* **299**, 976–979
 33. Labuda, M., Morgan, K., and Glorieux, F.H. (1990) Mapping autosomal recessive vitamin D dependency type 1 to chromosomal 12q14 by linkage analysis. *Am. J. Hum. Genet.* **47**, 28–36
 34. Kitanaka, S., Murayama, A., Sakaki, T., Inoue, K., Seino, Y., Fukumoto, S., Shima, M., Yukizane, S., Takayanagi, M., Numi, H., Takeyama, K., and Kato, S. (1999) No enzyme activity of 25-hydroxyvitamin D₃ 1 α -hydroxylase coexpression in pseudovitamin D-deficiency rickets with mild clinical manifestation. *J. Clin. Endocrinol. Metab.* **84**, 4111–4117
 35. Portale, A.A., Halloran, B.P., Morris, R.C., Jr. (1989) Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. *J. Clin. Invest.* **83**, 1494–1499
 36. Sawada, N., Sakaki, T., Kitanaka, S., Takeyama, K., Kato, S., and Inouye, K. (1999) Enzymatic properties of human 25-hydroxyvitamin D₃ 1 α -hydroxylase coexpression with adrenodoxin and NADPH-adrenodoxin reductase in *Escherichia coli*. *Eur. J. Biochem.* **265**, 950–956
 37. Sakaki, T., Sawada, N., Takeyama, K., Kato, S., and Inouye, K. (1999) Enzymatic properties of mouse 25-hydroxyvitamin D₃ 1 α -hydroxylase expressed in *Escherichia coli*. *Eur. J. Biochem.* **259**, 731–738
 38. Kawashima, H., Torikai, S., and Kurokawa, K. (1981) Localization of 25-hydroxyvitamin D₃ 1 α -hydroxylase along the rat nephron. *Proc. Natl. Acad. Sci. USA* **78**, 1199–1203
 39. Murayama, A., Takeyama, K., Kitanaka, S., Kadera, Y., Kawaguchi, Y., Hosoya, T., and Kato, S. (1999) Positive and negative regulations of the renal 25-hydroxyvitamin D₃ 1 α -hydroxylase gene by parathyroid hormone, calcitonin, and 1 α , 25(OH)₂D₃ in intact animals. *Endocrinology* **140**, 2224–2231
 40. Henry, H.L. (1979) Regulation of the hydroxylation of 25-hydroxyvitamin D₃ 1 α -hydroxylase *in vivo* and in primary cultures of chick kidney cells. *J. Biol. Chem.* **254**, 2722–2729
 41. Henry, H.L. (1985) Parathyroid hormone modulation of 25-hydroxyvitamin D₃ metabolism by cultured chick kidney cells is mimicked and enhanced by forskolin. *Endocrinology* **116**, 503–507
 42. Brenza, H., Kimmel-Jehan, C., Jehan, F., Shinki, T., Wakino, S., Anazawa, M., Suda, T., and DeLuca, H.F. (1998) Parathyroid hormone activation of the rat 25-hydroxyvitamin D₃ 1 α -hydroxylase gene promoter. *Proc. Natl. Acad. Sci. USA* **95**, 1387–1391
 43. Murayama, A., Takeyama, K., Kitanaka, S., Kadera, Y., Hosoya, T., and Kato, S. (1998) The promoter of the human 25-hydroxyvitamin D₃ 1 α -hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 α , 25(OH)₂D₃. *Biochem. Biophys. Res. Commun.* **249**, 121–126
 44. Demay, M.B., Kiernan, M.S., DeLuca, H.F., and Kronenberg, H.M. (1992) Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D receptor and mediate transcriptional response to 1,25-dihydroxyvitamin D. *Proc. Natl. Acad. Sci. USA* **89**, 8097–8101
 45. Mackey, S.L., Heymont, J.L., Kronenberg, H.M., and Demay, M.B. (1996) Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid X receptor. *Mol. Endocrinol.* **10**, 298–305